Abbott: 3 Key Takeaways for Long-Term Investors
Key Points
Abbott announced a tax-free spin-off of its nutrition business.
Third-quarter comparable sales grew 7% year over year.
Cancer diagnostics sales grew 14% on Cologuard demand.
- Motley Fool Issues Rare "Total Conviction" Buy Alert ›
On its third quarter of 2026 earnings call, held on Oct. 21, 2026, Abbott (NYSE:ABT) announced its plan to spin off its nutrition business into an independent public company. Shedding consumer nutrition sharpens focus on higher-margin medical technologies and diagnostics. The move leaves behind an enterprise with faster underlying sales expansion. Three takeaways from the call stand out.
1. Spinning Off Nutrition Isolates High-Margin Healthcare Growth
Separating adult and pediatric nutrition creates a pure-play consumer health business while shifting the remaining portfolio toward faster-growing medical devices and diagnostics. Abbott expects this structural change to boost sales growth rates and expand overall profit margins.
The nutrition market has evolved over time, with the pace of change accelerating significantly in recent years. What was once predominantly viewed as a healthcare market, almost exclusively shaped by healthcare professionals, has increasingly become a market shaped by changing consumer preferences, wellness trends, and retail execution. While this market evolution is not inherently positive or negative, it has fundamentally changed the environment in which we operate.
-- Robert Ford, Chairman and Chief Executive Officer
2. Cancer Diagnostics Drive Core Testing Revenue Acceleration
Expanding precision oncology and colorectal screening tools gives the diagnostic segment a reliable growth engine. Integrating advanced screening platforms increases test volume across clinical healthcare networks.
In cancer diagnostics, sales growth of 14% was driven by Cologuard and contributions to growth from our precision oncology and international businesses. In September, we launched our first blood-based colorectal cancer screening test.
-- Robert Ford, Chairman and Chief Executive Officer
3. Pulsed Field Ablation Powers Electrophysiology Expansion
New catheter technology and expanding regulatory approvals in cardiac care are accelerating market share gains in global electrophysiology. Full commercial releases in major markets position the medical device segment to outpace historical growth trends.
Growth was well-balanced across the portfolio, led by double-digit growth in electrophysiology and rhythm management. In electrophysiology, our third quarter results reflect the early beginning of our growth acceleration phase.
-- Robert Ford, Chairman and Chief Executive Officer
Looking Ahead
Third-quarter performance reflects accelerating top-line momentum, with medical devices and specialized pharmaceuticals driving operational gains across global healthcare networks. Long-term commercial strength rests on proprietary hardware pipelines, established clinical distribution channels, and strict pricing discipline in international markets.
Strategic attention centers on regulatory approval timelines for cardiac ablation catheters and expanded reimbursement coverage for continuous glucose sensors.
Spinning off the nutrition division sharpens the corporate structure around high-margin technology, directing capital toward high-return medical research while preserving dividend continuity and balance sheet strength.
Following the separation, Abbott will remain one of the largest, most diversified and fastest-growing healthcare companies in the world. The Abbott portfolio will consist of even stronger mix of higher growth, higher margin businesses powered by technology and innovation. As a result, we expect Abbott's sales growth to accelerate and margin profiles to expand.
-- Robert Ford, Chairman and Chief Executive Officer
Execution in core laboratory diagnostics and global electrophysiology remains the primary driver of sustained valuation creation.
Innovation continues to be a key differentiator for Abbott, highlighted by multiple new product approvals and launches that further strengthen our ability to deliver sustainable growth in the years ahead.
-- Robert Ford, Chairman and Chief Executive Officer
Should you buy stock in Abbott Laboratories right now?
Before you buy stock in Abbott Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Abbott Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $370,440!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,330,110!*
Now, it’s worth noting Stock Advisor’s total average return is 924% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 21, 2026.
The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
Recommended Articles
